Mizuho Maintains Bullish View on Sage Therapeutics (SAGE) as Conversation with New CEO Leaves Them More Comfortable
Tweet Send to a Friend
Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $81.00 price target on Sage Therapeutics (NASDAQ: SAGE) following a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
